We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Merck & Co. Inc. closed $34.98 below its 52-week high ($134.63), which the company achieved on June 25th.

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

The time to step into quality dividend payers is when the crowd forgets there's never a bad time to own a high-quality stock.

Analyst Akash Tewari of Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), retaining the price target of ...

2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive ...

Keytruda sales account for roughly 40% of Merck’s revenue, and the company has been focused on the 2028 patent expiration for ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Shares of Merck & Co. Inc. MRK shed 2.76% to $97.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and ...